Does This Biopharma Company’s “Pipeline In A Drug” Cancer Therapy Make Its Stock A Buy?
The clinical-stage biopharmaceutical company discussed in today’s article, which is focused on developing innovative cancer therapies.
The clinical-stage biopharmaceutical company discussed in today’s article, which is focused on developing innovative cancer therapies.
COVID case numbers are surging again thanks the Delta variant, and concerns that this will result in more lockdowns and travel restrictions may be part of the reason for the recent pullback in oil and gas prices.
With the fast-spreading Delta variant of the coronavirus taking hold in the U.S. and many countries around the world, we may just be entering the second inning of the COVID-19 pandemic.
“With the more contagious delta variant now dominant in the U.S. despite the widespread availability of vaccines, the need for effective treatments is once again growing more urgent.”
“Cancer treatments have remained a hotbed for biotech companies.”
The company’s drug for wet AMD had proven to help with the disorder, and thus it seems highly likely it will be approved.
“It was a difficult first half for biotech stocks, once again underscoring how conditions may seem so ideal but investment returns can still be hard to generate.”
“Wall Street analysts following these biotechs have high expectations for the drugs they’re developing and in one case already marketing.
If you feel like biotech stocks tend to go down right after you buy them, you’re not alone – and today’s article provides some important insights into what’s going on.
New stocks to watch in 2021.